Merger Control Defense: Economic Trends & Key Strategies

Competition remedies fall into two categories: structural remedies (divestments) and access remedies. Access remedies are required when vertically integrated parties might withhold inputs from downstream competitors, requiring commitments to provide access on transparent, non-discriminatory terms. Implementation often involves monitoring trustees appointed by the Commission, who act as the regulator's eyes. Complex technical markets may require additional technical experts. Waiving commitments requires demonstrating significant permanent market changes and sufficient time passage. Different regulators have varying attitudes toward behavioral commitments, with some like the European Commission willing to accept them as part of a mix with structural remedies, while others like the UK's CMA prefer structural changes.

Antitrust authorities can impose two types of remedies: structural remedies involve the sale or separation of business units, while behavioral remedies involve changes in how the company operates. The Department of Justice has proposed structural remedies for Google, which could include the separation of Chrome and Android. Google has argued that such separation could break the functionality and value of these products, which have been developed with significant investment. The remedies also include prohibiting default browser agreements and requiring Google to provide competitors with access to underlying data used to construct search results. Google contends that forcing the company to share search data would risk user privacy and security.

Structural remedies are the norm, while behavioral remedies are the exception. In the Microsoft-Activision case, the EU and UK had different approaches to remedies, with the EU accepting a license for Ubisoft while the UK had a different approach. Structural remedies are preferred because they are more permanent and less likely to be circumvented. Behavioral remedies are only acceptable when they are very targeted (like API issues) and when structural remedies are not feasible. This reflects the general principle that structural remedies are preferred in merger control. Competition enforcers represent different sovereigns and must enforce their own laws, making independent decisions. However, there is a responsibility to communicate, talk, and learn from each other. When done right, there is often convergence because enforcers are learning the same facts and implying similar analyses.

Competition authorities have raised the bar on accepting remedies, with some behavioral remedies accepted in the early 2000s still on the books, which is inappropriate. There is a conscious preference for structural remedies, particularly simple structural remedies. The Norwegian Competition Authority is generally hesitant to approve mergers based on behavioral remedies alone, as they do not change incentives or opportunities to exploit market power sufficiently. In the period 2004-2020, they had 86 merger cases and approved 30 with remedies. Structural remedies are preferred but difficult to implement. Challenges include finding a suitable and independent buyer who must be sufficiently relevant, able to verify ability to pay, have no close connections to the seller, and not become dependent on the seller. The sale must be sufficiently substantial to secure the required level of competition, sometimes requiring selling out the 'crown jewels.' Japan's JFTC prefers structural remedies but recently approved behavioral remedies in the Google-Fitbit merger review. The remedy included three parts: separation of health data from Google's advertising arm, access to information, and nondiscriminatory access to the Android API. The remedy is at least 10 years long with option to extend to 20 years, with a trustee reporting every six months. For complex mergers, Japan employed a structural model for two simultaneous mergers in the petroleum derivative products market, taking into account both product markets and ownership by upstream firms. Remedies included divestitures and an innovative remedy ensuring import pressure by reducing rivals' costs to import substitute products through legal stockpile requirements. Brazil's competition authority has seen increasing merger acquisitions, with 2021 being a record year with around 600 cases. 10% are complex cases requiring structural or behavioral remedies. Brazil has a remedy guideline showing preferred types of remedies, with structural remedies being best practice but behavioral remedies necessary when structural remedies cannot be applied. The authority knows behavioral remedies are hard to monitor with high costs and uncertain effectiveness. Spain's competition authority learned lessons from a 2009 case where Gas Natural merged with Union Fenosa, with a structural remedy requiring divestiture of thermal power plants. The energy market changed dramatically, making divestiture impossible. The authority adapted the obligation to monitor an option for ten years. This experience reinforced the preference for structural remedies with up-from-buyers, though authorities must not overestimate the possibility of finding buyers. Spain has combined behavioral with structural remedies when divesting assets would need time for the buyer to appropriate goodwill. In the cement industry case, they divested a silo to an upfront buyer but also imposed an obligation on the seller to provide supply of cement to the buyer's clients. For behavioral remedies, Spain normally imposes three plus six years, with ability to extend. Spain has a monitoring unit responsible for monitoring remedies, particularly behavioral ones. Competition authorities conduct ex post evaluations of merger decisions to assess whether they cleared mergers that shouldn't have been cleared or made mistakes in the other direction. Spain has published retrospective analyses on vertical mergers, digital mergers, and entry and expansion. The Norwegian Competition Authority has reviewed cases over 16 years and blocked one merger, with more than half of approved transactions involving structural remedies. In a recent financial sector case, the biggest bank wanted to buy the most popular bank (a significant challenger with innovative solutions and lower prices). The authority blocked the transaction, proposing remedies that were not relevant enough. The decision was appealed to the Competition Complaints Board, which concluded against the authority, raising questions about the threshold for interference. Japan's JFTC conducts retrospectives every two to four years, with research done by academics outside the authority. The authority has updated its economic analysis team to an economic analysis office and hired more economists and data scientists, hoping to do more retrospectives including evaluating remedies. Brazil's competition authority conducts ex post evaluations, including a case where Go bought Webjet in civil aviation. The analysis showed an 8% reduction in ticket prices and 28% increase in seat offers, confirming the merger decision. The UK Competition and Markets Authority has published a state of competition report for the UK market, finding that concentration has increased and markups have increased, similar to findings in the US and other countries. The UK has a markets regime where if there are problems in particular sectors, they can intervene and potentially break up companies. Norway's new head of competition authority wants a better sense of the whole situation in some markets to consider not just merger questions but whether authorities should be able to consider markets in a bigger context. This involves considering whether there are enough players in critical markets and whether there are entry barriers. Competition authorities are being asked to address inflation and high prices in various sectors, requiring careful consideration of whether problems are competition-related or require other policy responses.

In merger regulation, the Competition and Markets Authority (CMA) evaluates remedies based on proportionality, preferring structural remedies (divestiture or prohibition) over behavioral remedies (licensing agreements) when structural options are feasible, as structural remedies more effectively address competition concerns without requiring ongoing monitoring. In the Microsoft-Activision case, the CMA identified potential substantial lessening of competition in console gaming and cloud gaming, with Microsoft proposing 10-year licensing agreements to Sony, Nintendo, and Nvidia as behavioral remedies, while Sony argued for prohibition or divestiture, highlighting the ongoing debate about whether behavioral remedies can adequately address competition concerns in dynamic industries like gaming.

The failing firm defense allows mergers to proceed when one party is failing and no other buyer would purchase the company. In the FTC's case against Community Health Systems and Novent Health in Charlotte, North Carolina, the court applied this defense. The judge found that absent the merger, the hospitals would disappear because they had huge capital needs and were losing the technology arms race. The court agreed that while the merger wasn't perfect, it was the best chance to preserve those hospitals as assets. This case demonstrates that courts consider the unique policy concerns in healthcare—ensuring communities have access to healthcare—when evaluating mergers, and that the failing firm defense, while seldom successful, can work in healthcare contexts.

Historical antitrust cases like American Tobacco, Standard Oil, Alcoa, and International Shoe demonstrate that companies were often condemned for being large and efficient rather than for actual anti-competitive behavior, revealing that many antitrust prosecutions were based on flawed economic reasoning and political motivations rather than genuine market abuses.

The failing firm defense is a legal doctrine that permits otherwise anticompetitive mergers when a target firm faces imminent failure, requiring proof of three elements: (1) grave probability of imminent failure, (2) inability to reorganize under Chapter 11 bankruptcy, and (3) a good faith search for alternative purchasers offering equal or higher value with less competitive harm; this defense is distinct from the related but weaker 'flailing firm defense,' which argues that a target's market share is artificially inflated and will decline significantly post-merger, thereby reducing competitive concerns.

Antitrust law has historically rejected the defense that a challenged merger will result in economic efficiencies ancillary to competition in the relevant market. Courts have expressly and repeatedly rejected this argument, recognizing that claimed efficiencies do not necessarily translate to actual competitive benefits for consumers. This principle ensures that mergers cannot be approved based on theoretical efficiency gains that may not materialize or may be used as a pretext for anti-competitive behavior.

Traditional efficiency analysis fails when mergers facilitate tacit collusion rather than unilateral market power. The Miller-Kors beer joint venture case demonstrates this: despite convincing efficiency analyses and predicted savings, post-merger prices rose significantly because the merger enabled greater coordination among remaining competitors. Similarly, airline merger research shows consecutive mergers substantially increased multimarket contact, enabling collusive behavior that manifested in non-overlap routes. This reveals that unilateral effects analysis alone cannot capture all anti-competitive consequences, and that control groups used in retrospective studies may not actually be unaffected by merger-related coordination effects.

Tacit collusion is more likely when there are fewer firms in the market, higher discount rates (firms value future profits more), clearer profit signals, and stable market conditions; conversely, collusion is less likely when there are many firms, high entry barriers, differentiated products, unstable demand and costs, and dissimilar firm costs. Strategies like geographic market division, most-favored-customer clauses, and trigger strategies can facilitate tacit collusion by reducing incentives for price undercutting.

This lecture explains that while courts consider three criteria for collective dominance (transparency for monitoring, deterrence mechanisms, and absence of outsider disruption), explicit collusion may be more concerning than tacit collusion in merger analysis. The vitamins cartel case demonstrates that even firms with 10 years of explicit collusion experience failed to sustain tacit collusion after the conspiracy ended. Key factors increasing explicit collusion risk include higher profitability, easier implementation of collusive structures, and prior history of collusion. The industrial tubes case shows that explicit collusion can succeed even when tacit collusion would be difficult, due to communication and transfer mechanisms that overcome transparency barriers.

The collusion detection round tests the ability to identify coordinated behavior among impostors. When multiple panelists give similar answers or coordinate their responses, it reveals who is working together versus who has genuine personal knowledge. This round tests the ability to detect patterns and inconsistencies in responses.